Toshiba America Medical Systems, Inc. has received FDA clearance for two new CT clinical applications that will improve throughput and enhance workflow, while further reducing contrast and radiation dosage. The applications, SURECardio™ Prospective and Variable Helical Pitch (vHP), are available for new Toshiba AquilionTM 32- and 64-slice CT systems.

SURECardio Prospective

Toshiba’s SURECardio Prospective helps reduce patient dose by up to 80 percent during coronary CTA exams by using a helical acquisition technique to provide one continuous image instead of multiple images produced by the current step-and-shoot techniques. SURECardio Prospective will automatically detect and adjust to patients with arrthymia, providing quicker, more conclusive exam results.

SURECardio Prospective automates scan parameters and reconstruction based on the patient’s heart rate. It also speeds exam time and eliminates the need to use additional contrast as with the step-and-shoot method.